CY-101 + Pembrolizumab
Colorectal Cancer
Key Facts
About Cytovation
Cytovation ASA is a clinical-stage biotechnology company based in Norway that focuses on precision medicine for patients with β-catenin driven tumors. Built on over 15 years of research from the University of Bergen and Haukeland University Hospital, the company has developed CY-101, a stable synthetic peptide that selectively targets cancer cell membranes while inhibiting the β-catenin pathway. With multiple completed Phase I trials and upcoming Phase II studies, Cytovation aims to expand immunotherapy benefits to a broader range of cancer patients.
View full company profileAbout Cytovation
Cytovation ASA is a clinical-stage biotechnology company based in Norway that focuses on precision medicine for patients with β-catenin driven tumors. Built on over 15 years of research from the University of Bergen and Haukeland University Hospital, the company has developed CY-101, a stable synthetic peptide that selectively targets cancer cell membranes while inhibiting the β-catenin pathway. With multiple completed Phase I trials and upcoming Phase II studies, Cytovation aims to expand immunotherapy benefits to a broader range of cancer patients.
View full company profileTherapeutic Areas
Other Colorectal Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| LONSURF | Otsuka Holdings | Commercial |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |
| Botensilimab + Balstilimab | Agenus | Phase 2 |
| Undisclosed Degrader (ABM Program) | Captor Therapeutics | Preclinical |